BC Extra | Sep 24, 2019
Financial News

Amphivena to expand clinical program, T cell engager pipeline with $62M series C

Amphivena Therapeutics Inc. will use its $62 million series C to advance its lead candidate in solid tumors and build out its T cell engager portfolio. The round, closed Tuesday, was co-led by new investors...
BioCentury | Dec 8, 2018
Product Development

Intermittent move beyond Blincyto

A swath of data at ASH shows that companies have been able to move beyond the 28-day continuous dosing of Amgen Inc.’s first-generation BiTE, Blincyto, to build next-generation antibodies with more convenient, intermittent dosing and...
BioCentury | Dec 1, 2018
Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
BC Innovations | Jun 25, 2015
Product R&D

Cellectis' UCART-ography

A year after Pfizer Inc. threw its weight behind Cellectis S.A. 's chimeric antigen receptor (CAR) T cell platform, the biotech has signed a three-year partnership with Weill Cornell Medical College to test whether its...
BC Innovations | Jun 11, 2015
Product R&D

All four one

Amphivena Therapeutics Inc. licensed Affimed N.V. 's tetravalent antibody-mimetic technology two years ago to create blood cancer therapeutics that would be simpler to use and safer than CAR T cell therapies. Now, the start-up has...
Items per page:
1 - 5 of 5